ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
07/29/201614:21:00La Commission européenne délivre une autorisation de mise sur l...
07/29/201613:47:00Merck Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29/201610:59:00La Commissione europea concede l'autorizzazione all'immissione...
07/29/201608:40:00Merck Revenue Rises on Cancer, Hepatitis Treatments
07/29/201608:24:00Merck Revenue Rises on Cancer, Hepatitis Treatments
07/29/201607:00:00European Commission Grants Marketing Authorisation for MSD’s Z...
07/29/201607:00:00Europäische Kommission erteilt MSD Marktzulassung für ZEPATIER™ (El...
07/29/201606:59:22Current Report Filing (8-k)
07/29/201606:45:00Merck Announces Second-Quarter 2016 Financial Results
07/28/201602:46:00Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker...
07/26/201613:04:00From Farm to Pharma, Former CEO Recalls First Job as Laborer
07/26/201612:50:00Merck Announces Fourth-Quarter 2016 Dividend
07/25/201617:20:00Gilead Sales of Hepatitis C Drugs Fall 19%
07/25/201608:05:00NewLink Genetics Announces Merck Receives Breakthrough Therapy...
07/25/201608:00:00Merck Receives Breakthrough Therapy Designation from FDA & PRIME...
07/22/201607:00:00Data for Merck's Investigational Once-Daily Formulation of ISENTRESS®...
07/21/201617:00:00Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner...
07/21/201616:30:00Merck Provides Regulatory Update on Biologics Licensing Application...
07/18/201612:08:00MARKET SNAPSHOT: Dow On Track For Record Closing High As Tech...
07/18/201602:10:00China's Food and Drug Administration Approves GlaxoSmithKline's...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad